http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Needle guide를 사용한 입체정위생검술의 유용성에 대한 고찰
이은혜(Eun-Hye Lee):장동혁(Dong-Hyuk Jang):문영주(Young-Ju Moon):권영호(Young-Ho Kwon) 대한영상의학기술학회 2016 대한영상의학기술학회 논문지 Vol.2016 No.1
목 적 : 입체정위 생검술을 일반적인 방법으로 시행하였을 때와 needle guide를 사용하여 시술을 진행했을 때의 차이를 비교해 봄으로써 초기 유방암 진단 효과의 유용성을 평가 해 보고자 하였다. 대상 및 방법 : 2011년 11월 25일부터 본원을 내원한 여성 환자 가운데 유방촬영 장비를 이용하여 입체정위 생검술을 시행한 83명을 대상으로 하였다. 연구 대상자의 평균연령은 49.5 ± 6.7 이었다. 두 가지 방법의 전체 시술 시간, 실제 시술 시간, 흡수선량을 비교하고, 영상의학과 전문의의 판단으로 생검이 가능한 유방 두께를 조사하였다. 또한 연구 대상의 유형을 병변이 생기는 위치, 유방의유형, BI-RADS Category에 따라 구분하고 이를 분석하였다. 결 과 : 병변의 위치, 유방의 유형, BI-RADS Category는 통계적으로 유의한 차이가 없었다(p>0.05). 유방의 두께는 일반적인 방법과 Needle guide를 이용한 방법에서 유의한 차이를 보이지 않았다(p>0.05). 흡수선량은 일반적인 방법이 11.63 ± 3.01로 Needle guide를 이용한 방법의 14.68 ± 4.21보다 적었고(p<0.05), 전체 시술 시간과 실제 시술 시간은 Needle guide를 이용한 방법이 짧게 나타났다(p<0.05). 결 론 : Needle guide를 사용한 방법이 일반적인 방법보다 선량이 더 많다는 것에 제한점이 있으나, 빠른 시간 내에 검사가 이루어지며 시술 후 유방 내 미세 석회화의 잔존유무와 생검한 조직을 한 대의 장비로 신속하게 확인할 수 있다는 장점이 있었다. 그러므로 조기 유방암의 진단에 유용할 것으로 사료된다. Purpose : The purpose was to compare the difference of treatment in using the general method of stereotactic mammotome biopsy and when using the needle guide to evaluate the effectiveness of early breast cancer diagnosis. Subject and Methods : Among the female patients visiting the hospital from November 25, 2011, 83 patients performed with stereotactic mammotome biopsy using the mammography equipment were selected as the subject. The average age of the subjects of this study was 49.5 ± 6.7. The total procedure time, actual procedure time, and absorbed dose of the two methods were compared, and under the decision of the radiologist, the breast thickness possible for biopsy was investigated. In addition, the types of the study subject were classified according to the location of the lesion, breast type and BI-RADS Category and were analyzed. Results : The location of the lesion, breast type, and BI-RADS Category showed no statistically significant difference (p>0.05). For the thickness of the breast, the general method and the method using needle guide showed no significant difference (p>0.05). For the absorbed dose, the general method was 11.63 ± 3.01 to be less than the Needle guide method of 14.68 ± 4.21 (p<0.05), and for the total procedure time and actual procedure time, the method using the needle guide showed to be shorter (p<0.05). Conclusion : There was limitation of having more dose than the general method, but the test was enabled in shorter time, and also had advantage of verifying the existence of residual fine calcification in the breast quickly after the procedure. Therefore, it is considered that the method using the needle guide is more effective in the early breast cancer diagnosis.
Performance Analysis of DS/CDMA DPSK System with PLL Gain
Jang, Moon-Kee,Kim, Joon-Bae,Kim, Won-Sub,Ju, Jong-Hyuk,Park, Jin-Soo 청주대학교 산업과학연구소 2003 産業科學硏究 Vol.20 No.2
이동통신채널에서 수신된 신호는 다중경로 페이딩에 의해 진폭과 위상에 영향을 받게 된다 따라서 본 논문에서는 송수신기 사이에서 발생된 위상차를 Tikhonov 확률밀도함수로 모델링하고 PLL 이득에 따른 DS/CDMA/ DPSK 시스템의 성능을 분석하였다. 그 결과, 본 논문에서 제안된 시스템에 PLL의 이득을 조정함으로써 위상이 완전 동기된 DPSK 시스템의 성능에 근접하게 됨을 알 수 있었다 컴퓨터 모의실험결과, 제안된 시스템에서 PLL 이득이 1dB인 경우 두 시스템간의 성능차는 4.8dB, PLL이득이 7dB인 경우 0.4dB로 근접하는 것을 알 수 있었으며 PLL 이득을 30dB 이상인 경우 제안된 시스템이 완전동기된 DPSK 시스템과 같은 성능을 나타냄을 알 수 있었다 A received signal in mobile communication environments exhibits variation in both amplitude and phase due to the multipath fading Therefore we analyzed the performance of DS/CDMA (Direct Sequence / Code Division Multiple Access) DPSK(Difference Phase Shift Keying) system for the variations of PLL(Phase Locked Loop) gain with Tikhonov probability density function, assuming that the phase difference between transmitter and receiver signals is phase error As a result, it is discovered that the performance of system could be improved by the control of PLL gain in compared w t h the DPSK system which does not consider the phase error If the PLL gain is 1dB, the difference of two systems is 48dB and 04dB at 7dB And if 30dB, it coincides From above, it also verified that the limit of gain is 30dB
Jang, Kang Won,Lee, Kyung Hye,Kim, Soo Hyuk,Jin, Taewon,Choi, Eun Young,Jeon, Hyun Ju,Kim, Eunsuk,Han, Ye Sun,Chung, Ji Hyung Wiley Subscription Services, Inc., A Wiley Company 2011 Journal of cellular biochemistry Vol.112 No.12
<P><B>Abstract</B></P><P>Transcriptional factor nuclear factor‐kappaB (NF‐κB) plays a crucial role in human breast cancer cell invasion and metastasis. The carboxyl terminus of Hsc70‐interacting protein (CHIP) is a U‐box‐type ubiquitin ligase that induces ubiquitination and proteasomal degradation of its substrate proteins. In this study, we investigated the role of CHIP in the NF‐κB pathway in the invasion of MDA‐MB‐231 cells, a highly aggressive breast cancer cell line. We showed that overexpression of CHIP significantly inhibits the invasion of the MDA‐MB‐231 cells. The overexpression of CHIP suppressed expression of urokinase plasminogen activator (uPA) and matrix metalloproteinase‐9 (MMP‐9) in MDA‐MB‐231 cells. Moreover, CHIP strongly inhibited the nuclear localization and the transcriptional activity of NF‐κB. The activation of the IkappaB kinase complex (IKK) was also blocked by CHIP overexpression. Importantly, CHIP overexpression resulted in a significant decrease in the level of TNF receptor‐associated factor 2 (TRAF2), an upstream key player in the NF‐κB pathway. However, the level of TRAF2 was restored after treatment with a proteasome inhibitor, MG‐132. Moreover, CHIP overexpression promoted the ubiquitination of TRAF2. We also found cell invasion significantly decreased in cells transfected with TRAF2 small interfering RNA (siRNA). In contrast, when CHIP expression was suppressed by siRNA in poorly invasive MCF‐7 cells, cell invasion significantly increased in conjunction with enhanced NF‐κB activation and TRAF2 levels. Taken together, these results suggest that CHIP regulates NF‐κB‐mediated cell invasion via the down‐regulation of TRAF2. J. Cell. Biochem. 112: 3612–3620, 2011. © 2011 Wiley Periodicals, Inc.</P>
Jang, Yong Hyun,Hong, Nam-Soo,Moon, Sun Young,Eun, Dong Hyuk,Lee, Won Kee,Chi, Seong Geun,Kim, Jun Young,Lee, Weon Ju,Lee, Seok-Jong,Kim, Do Won S. Karger AG 2017 Dermatology Vol.233 No.2
<P>Background: In alopecia totalis (AT) and alopecia universalis (AU), the chance of full hair regrowth is known to be less than 10%. However, this information is based on a few older studies conducted in the 1950s and 1960s. Objective: We investigated the current long-term prognosis of individuals with AT/AU. Methods: A retrospective chart review was performed in patients with AT/AU between 1994 and 2005. Outcome data were collected by reviewing outpatient clinical files or by phone interviews. Finally, the long-term assessment of 70 patients with valid outcome data was performed. Results: Twelve out of 70 patients with AT/AU (17.1%) had complete hair regrowth. Five out of 24 patients with AT (20.8%) showed complete hair regrowth, and 7 of 46 patients with AU (15.2%) achieved complete regrowth. Seventeen out of 70 patients with AT/AU (24.2%) reported hair regrowth greater than or equal to 90%. Thirty patients with AU (65.2%) remained in an alopecic state without improvement, while 5 patients with AT (20.8%) showed no hair regrowth. Conclusion: Our results suggest that the long-term prognosis of AT/AU is more favorable than previously thought. However, the clinical burden of AT/AU is still substantial. (C) 2017 S. Karger AG, Basel</P>
프로브 구조를 이용한 Ka 대역 도파관-마이크로스트립 트랜지션의 설계 및 제작
권혁자(Hyuk-Ja Kwon),이성주(Sung-Ju Lee),장호준(Ho-Joon Jang) 대한전자공학회 2008 電子工學會論文誌-TC (Telecommunications) Vol.45 No.7
본 논문에서는 Ka 대역에서 동작하는 송수신기에 쉽게 집적화 할 수 있는 프로브 구조를 이용한 도파관-마이크로스트립 트랜지션을 설계 및 제작하였다. 도파관-마이크로스트립 트랜지션은 프로브, 인덕턴스 선로, λ/4 임피던스 변환기, 그리고 50 Ω 마이크로스트립 선로로 구성되어있으며, 각 구성 요소들의 특성 임피던스 및 길이를 시뮬레이션을 통해 최적화하였다. 제작된 트랜지션의 측정결과, 30 ~ 40 ㎓ 대역 내에서 평균 1.3 ㏈의 삽입손실 특성, 14 ㏈이하의 입출력 반사 손실특성을 나타내었다. 마이크로스트립 선로 및 입출력 도파관의 손실을 고려하여 하나의 변환 구조 당 삽입 손실은 0.5 ~ 0.6 ㏈ 정도이다. We report the waveguide to microstrip transition using probe structure for Ka-band transceiver. The waveguide to microstrip transition is composed of probe, inductive line, λ/4 impedance transformer, and 50 Ω microstrip line. For design of the transition, we optimized the characteristic impedances and the lengths of the component parts. The fabricated transition exhibits an insertion loss of 1.3 dB and the input/output return losses of below 14 ㏈ between 30 and 40 ㎓. The insertion loss of each transition is about 0.5 ~ 0.6 ㏈, considering the losses in the microstrip line and input/output waveguides.
( Dong Hyuk Eun ),( Seok Min Kim ),( Min Ji Kim ),( Jun Young Kim ),( Yong Hyun Jang ),( Weon Ju Lee ),( Do Won Kim ),( Seok-jong Lee ) 대한피부과학회 2017 대한피부과학회 학술발표대회집 Vol.69 No.1
In-transit metastasis of malignant melanoma is a unique pattern of recurrence that occurs in up to 10 percent of patients with melanoma. Among various modalities, topical DPCP has shown meaningful but limited results in in-transit metastasis. Recently, a case treated with IL-2 intralesional injection was reported with good result. A 68-year-old man visited our clinic with recalcitrant eroded patch on Rt hallux for 2 years confirmed as malignant melanoma. Thereafter amputation of Rt hallux with ipsilateral inguinal sentinel node biopsy was done with no regional metastasis (pSTAGE IIC (T4bN0M0)). After 7 months later, complete Rt inguinal node dissection due to nodal metastasis was performed. Six-month later, multiple papulonodules were appeared on Rt groin and calf and were diagnosed as in-transit metastasis and then topical DPCP was started. After 3 months of DPCP treatment, lesion was remarkably improved, but a few months later, recurrence was confirmed by punch biopsy on Rt knee, ingenol mebutate 0.05% in addition to topical DPCP was started together. But there was no improvement for 1.5 months. Then, IL-2 intralesional injection was started together with topical DPCP. After 11 times of IL-2 with topical DPCP once a week, there were no tumor cells on surgical specimen. We report an educational case to highlight the treatment effect of IL-2 intralesional injection and topical DPCP on in-transit metastasis of malignant melanoma.